Sign In
Buy BIAF
$1.69
+0.0100 (+0.595%)
At Close: Jun 03, 2026
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
08:00am, Friday, 26'th Sep 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies shares 3 new case studies in which CyPath Lung detected Stage 1A lung cancer or prevented unnecessary invasive procedures.
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
08:15am, Wednesday, 17'th Sep 2025
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced it will effect a 1-for-30 reverse split of its common stock at the opening of trading on September 19, 2025.
BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth
04:00pm, Thursday, 21'st Aug 2025
bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.
bioAffinity Technologies Appoints New Members to Board of Directors
08:00am, Monday, 18'th Aug 2025
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies appoints leaders in corporate finance and the diagnosis and treatment of asthma and COPD to its Board of Directors.
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closes private placement and warrant inducement transaction for approximately $1.2 million in gross proceeds.
bioAffinity Technologies Reports Second Quarter 2025 Results
08:00am, Thursday, 14'th Aug 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports Q2 2025 results; CyPath Lung revenues up 62% year-over-year in first six months of 2025.
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of private placement and warrant inducement transaction.
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
08:00am, Wednesday, 13'th Aug 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a significant surge in commercial sales of CyPath® Lung with back-to-back record monthly sales in June and July.
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
08:00am, Tuesday, 29'th Jul 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--CyPath® Lung detects a rare mucinous adenocarcinoma at Stage 1A in a high-risk individual whose previous tests suggested a low probability of cancer.
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
09:00am, Tuesday, 22'nd Jul 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Canada grants bioAffinity Technologies new patent that protects its proprietary technology that powers its flagship product, CyPath® Lung.
bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic
09:00am, Tuesday, 15'th Jul 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies has received notification of allowance from China for a patent on its technology for predicting the likelihood of lung cancer.
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
09:00am, Thursday, 26'th Jun 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity scientists present breakthrough research on using siRNAs to knock down two receptors on the cell membrane to selectively kill cancer cells.
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board
09:00am, Wednesday, 11'th Jun 2025
SAN ANTONIO--(BUSINESS WIRE)-- #ALA--bioAffinity CEO Maria Zannes joins the American Lung Association in Texas' Leadership Board of to advance prevention and treatment of lung disease.
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
09:00am, Wednesday, 28'th May 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces new patent for method of selectively killing cancer by targeting two specific receptors on the cell membrane.
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
01:15pm, Tuesday, 20'th May 2025
bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.
